Distinctive Cytokines as Biomarkers Predicting Fatal Outcome of Severe Staphylococcus aureus Bacteremia in Mice by Berg, S. (Sanne) van den et al.
Distinctive Cytokines as Biomarkers Predicting Fatal
Outcome of Severe Staphylococcus aureus Bacteremia in
Mice
Sanne van den Berg1*, Jon D. Laman2, Louis Boon3, Marian T. ten Kate1, Gerjo J. de Knegt1,
Rob M. Verdijk4, Henri A. Verbrugh1, Jan L. Nouwen1, Irma A. J. M. Bakker-Woudenberg1
1Department of Medical Microbiology and Infectious Diseases, Erasmus University Medical Centre, Rotterdam, The Netherlands, 2Department of Immunology, Erasmus
University Medical Centre, Rotterdam, The Netherlands, 3 Bioceros BV, Utrecht, The Netherlands, 4Department of Pathology, Erasmus University Medical Centre,
Rotterdam, The Netherlands
Abstract
Invasive Staphylococcus aureus infections are frequently associated with bacteraemia. To support clinical decisions on
antibiotic therapy, there is an urgent need for reliable markers as predictors of infection outcome. In the present study in
mice, bacteraemia was established by intravenous inoculation of a clinical S. aureus isolate at the LD50 inoculum. As
potential biomarkers for fatal outcome, blood culture (qualitative and quantitative), serum levels of C-reactive protein (CRP),
as well as 31 selected cytokines and chemokines were assessed during the first three days of infection. A positive S. aureus
blood culture, the quantitative blood culture, CRP levels, and levels of eight cytokines were indicative for the presence of S.
aureus bacteraemia. However, only tumor necrosis factor (TNF) a, interleukin (IL) 1a, and keratinocyte chemoattractant (KC;
a functional homologue of human IL-8) were each significantly elevated in eventually non-surviving infected mice versus
eventually surviving infected mice. In severe S. aureus bacteraemia in mice, TNF-a, IL-1a, and KC are biomarkers predicting
fatal outcome of infection. KC was a biomarker elevated irrespective the progression of infection, which is very interesting
regarding clinical application in view of the heterogeneity of patients experiencing bacteraemia in this respect.
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Introduction
Staphylococcus aureus is an important opportunistic pathogen that
causes a variety of infections, from relatively mild infections such
as skin infections and food poisoning, to life-threatening conditions
such as necrotizing pneumonia and osteomyelitis [1]. The invasive
infections are frequently associated with S. aureus bacteremia [2].
Shorr et al. showed that S. aureus was the most common bacterial
isolate in 6,697 bloodstream infections in the USA, and S. aureus
was more strongly associated with mortality than any other
bacterial pathogen [3].
A clinically significant bacteremia is generally defined as the
isolation of bacteria from one or more peripheral venous blood
culture samples collected from a patient with associated relevant
clinical symptoms of systemic infection as defined on the 2001
International Sepsis Definitions Conference [4]. When sepsis is
strongly suspected, an appropriate treatment regimen for each
patient is designed.
Blood culture confirms the presence of bacteremia, and allows
identification of the causative infectious agent. Rapid diagnosis
and (antibiotic) treatment of bacteremia is essential, as any delay in
treatment may lead to worse outcome. On the other hand,
antibiotic use should be limited, and proper decision on initiating
antibiotic therapy or adjustment of antibiotic choice in therapy
already started in severe bacteremia is highly important. Knowl-
edge of how to predict fatal outcome in patients with S. aureus
bacteremia is currently lacking. To support clinical decisions on
these issues, there is an urgent need for reliable markers that can
be used as predictors of outcome of infection.
An obvious candidate biomarker may be C-reactive protein
(CRP), which is the classic acute phase protein. CRP is released by
the liver to the blood, and activates the complement system. This
marker is currently used to determine inflammation and tissue
damage [5]. Systemic levels of CRP are elevated in septic
traumatized patients compared to non-septic traumatized patients
[6]. Synthesis of CRP by hepatocytes starts very rapidly, and CRP
can be detected in plasma after 6–12 hours, and a plateau is
reached after 20–72 hours. Plasma half-life of CRP is about
19 hours [7–9].
Bacteremia can lead to sepsis and multiple organ failure, and
eventually to death when therapy fails. For many years, it was
assumed that sepsis is a consequence of an overwhelming
inflammatory reaction of the patient to microorganisms. Neutral-
ization of single pro-inflammatory cytokines like tumor necrosis
factor (TNF) a or interleukin (IL) 1 in animal models of sepsis
resulted in protection against lethal sepsis [10–14]. In contrast to
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these murine studies, inhibition of these cytokines has not provided
clinical benefit to patients with severe sepsis [15–20]. Therefore, it
is clear that not only the pro-inflammatory reaction forms the basis
for adverse outcome in sepsis, immune suppression by anti-
inflammatory reactions is involved as well. As cytokines are
important in sepsis, they are candidate biomarkers for presence
and fatal outcome of S. aureus bacteremia. Clinical studies
determined cytokine levels in sepsis or sepsis-like situations. Two
studies assessed cytokine levels in healthy volunteers after
lipopolysaccharide injection (LPS) injection. Dandona et al. [21]
found elevated serum levels of TNF-a, and Van der Poll et al. [22]
described a rise in IL-10 plasma levels. Cytokine levels in septic
patients were measured as well. These studies did not focus on a
single causative infectious agent. Levels of IL-1b [23], IL-2 [24],
IL-6 [23,25-28], IL-8 [24], IL-10 [22,23,26-28], TNF-a
[23,28,29], and IFN-c [28] were elevated in septic patients
compared to normal levels. Levels of IL-6 [23,26], IL-10 [22,30]
and TNF-a [30] were predictive for fatal outcome in patients with
sepsis, while IL-10 [23,26] levels were predictive for survival. It is
difficult to evaluate the value of changes in cytokine profile during
bacteremia in patients due to differences in the causative infectious
agents in these studies. In addition, only a limited number of
cytokines were included in these studies, which hinders the
comparison of results obtained from the various studies.
Hence, we hypothesized that cytokines are useful as biomarkers
for fatal outcome of S. aureus bacteremia. The present study in
mice was performed to identify biomarkers predicting fatal
outcome of severe S. aureus bacteremia. We focused on blood
culture, CRP, and selected cytokines. To this aim, we established
an in vivo model of severe S. aureus bacteremia in mice, using a
clinical S. aureus isolate. The use of a S. aureus inoculum resulting in
50% mortality allowed comparing eventually surviving infected
mice and eventually non-surviving infected mice in the same
model.
Materials and Methods
Bacteria
A clinical S. aureus isolate (isolate P), recovered from a septic
patient, was used. This isolate was kindly supplied by G. Buist
(University Medical Centre Groningen, The Netherlands) and
described by Ziebandt et al. (CA-MSSA, MLST type 7, agr-type 1,
pvl-negative) [31]. Staphylococci were grown overnight at 35uC on
Colombia III blood agar (Becton Dickinson, Breda, The Nether-
lands). Cultures of S. aureus, grown in Brain Heart Infusion broth
(Becton Dickinson, Breda, The Netherlands) until OD560 , 1.0,
were stored at –80uC.
Animals
Specified opportunistic pathogen-free (SOPF) female BALB/
cBYJ S. aureus-free mice (11-13 weeks at day of infection) were
obtained from Charles River (Saint-Germain-sur-l’Arbresle,
France), and were given food and water ad libitum. Before each
experiment, S. aureus-free status was checked by culture of fresh
fecal and nasal microbiota as well as by confirming the absence of
anti-staphylococcal IgG levels against 54 antigens using Luminex
technology [32].
Ethics statement
The experimental protocols adhered to the rules specified in the
Dutch Animal Experimentation Act (1977) and the published
Guidelines on the Protection of Experimental Animals by the
Council of the EC (1986). The Institutional Animal Care and Use
Committee of the Erasmus University Medical Centre Rotterdam
approved the present protocols.
S. aureus bacteremia
A suspension of S. aureus was defrosted and centrifuged for
10 minutes at 14.0006g. . The S. aureus pellet was resuspended in
saline, and diluted to obtain the desired inoculum. To establish
bacteremia, 100 mL of S. aureus isolate P was injected into the tail
vein.
Various S. aureus inocula, resulting in 0 – 100% mortality, were
injected intravenously (n = 5 per inoculum) to determine the
inoculum-dependent cumulative mouse mortality. Clinical signs of
illness in each mouse were evaluated twice daily. Mice with bad fur
were scored -2. Mice with bad fur and hunched back were scored -
3. Mice with bad fur and hunched back and that were instable,
were scored -4. These mice showed severe signs of illness and were
euthanized by CO2 exposure. Euthanized mice were considered as
death, as pilot experiments showed that mice with severe signs of
illness died before the end of the experiment. Animal survival 14
days after inoculation was monitored and cumulative mortality
was calculated. For experiments, groups of mice (n = 25) were
infected with a S. aureus inoculum at the 50% lethal dose (LD50).
Animal survival rate, body weight, and discomfort were monitored
over 14 days. From mice that were euthanized due to severe signs
of illness, blood, lung, spleen, liver, and kidneys were cultured to
confirm that they died because of S. aureus infection only.
At various intervals after infection, the bacterial load in blood
and infected organs was determined. Mice (n = 4 per time point)
were sacrificed at 1, 17, or 48 hours by CO2 exposure. A blood
sample was taken via (transcutaneous) cardiac puncture and
collected in a vial containing Lithium Heparin (Sarstedt, Etten-
Leur, The Netherlands). The lung, spleen, liver, and kidneys were
removed aseptically and homogenized (Polytron, Kinematica,
Luzern, Switzerland) in 2 mL of saline for 10 seconds at
30,000 rpm at room temperature. Undiluted homogenate suspen-
sions and blood and 10-fold serial dilutions of homogenates and
blood in saline were plated onto Colombia III blood agar. After
overnight incubation at 35uC colonies were counted.
The histopathological changes in infected tissues of non-
surviving, euthanized mice (n = 4) were determined in animals
sacrificed using an overdose of pentobarbital (Ceva Sante
Animale, Naaldwijk, The Netherlands). The in situ re-expanded
lungs and the other organs were processed as described before
[33]. Tissue sections (4 mm) were stained with haematoxylin and
eosin. A pathologist examined the sections microscopically.
Parameters to monitor infection progression and
outcome
Blood cultures. Blood was withdrawn from the tail artery of
infected mice at 17, 48, and 72 hours after infection (n= 25),
collected in a MicrovetteH CB300 capillary tube containing
Lithium Heparin (Sarstedt, Etten-Leur, The Netherlands) and
cultured as described above.
C-reactive protein. For quantification of CRP, blood was
withdrawn from the tail artery of infected mice at 1, 17, or
48 hours after infection. Blood was collected in a MicrovetteH
CB300 capillary tube (Sarstedt, Etten-Leur, The Netherlands) and
sera were prepared and stored at –80uC. To exclude effects of
animal handling, a control group receiving saline only was
included (n = 10). CRP was measured via solid phase ELISA kit
(LifeDiagnostics, West Chester, PA) according to the manufactur-
er’s instructions, as described by Reichelt et al. [34]. All samples
were run in duplicate and reported as an average of two
determinations.
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Cytokines. Cytokine concentrations in serum were assessed
at 1, 17, or 48 hours after infection. To exclude effects of animal
handling on cytokine levels, a control group receiving saline only
was included (n= 10). Cytokine levels were determined using the
MilliplexH MAP kit (Millipore, Amsterdam, The Netherlands) in
duplicate, following the manufacturer’s user manual using the
Luminex 100 instrument (Biomedical Diagnostics, Antwerpen,
Belgium). Selected cytokines were: granulocyte colony stimulating
factor (G-CSF), granulocyte monocyte colony stimulating factor
(GM-CSF), macrophage colony stimulating factor (M-CSF),
interferon (IFN) c, leukemia inhibitory factor (LIF), tumor necrosis
factor (TNF) a, interleukin (IL) 1a, IL-1b, IL-2, IL-3, IL-4, IL-5,
IL-6, IL-7, IL-10, IL-12p40, IL-12p70, IL-13, IL-15, and IL-17A.
Selected chemokines were: eotaxin (CCL1), IFN-c inducible
protein of 10 kDa (IP-10; CXCL10), keratinocyte chemoattractant
(KC; CXCL1; functional homologue of human IL-8 [35]),
lipopolysaccharide induced CXC chemokine (LIX; CXCL5-6),
monocyte chemoattractant protein 1 (MCP-1; CCL2), monokine
induced by IFN-c (MIG; CXCL9), macrophage inflammatory
protein 1a (MIP-1a; CCL3), MIP-1b (CCL4), MIP-2 (CXCL2),
the chemokine regulated-upon-activation normal T-cell expressed
and secreted (RANTES; CCL5), and vascular endothelial growth
factor (VEGF). Selected cytokines and chemokines are represen-
tative for both pro- and anti-inflammatory cytokines.
Statistical analysis. Quade’s rank analysis of covariance was
used to compare body weight of placebo-inoculated mice,
surviving infected mice and non-surviving infected mice. Fisher
exact test was used to compare numbers of mice with positive
blood cultures in groups of surviving infected mice versus non-
surviving infected mice. Also, S. aureus counts in blood and organs,
and serum levels of CRP and cytokines in groups of placebo-
inoculated mice, surviving infected mice and non-surviving
infected mice were compared using the Mann-Whitney U test.
Binary logistic regression analysis using all variables associated
with presence or fatal outcome of S. aureus bacteremia in the
Mann-Whitney U test (P-values , 0.01) was performed to
determine the biomarkers for presence and fatal outcome of S.
aureus bacteremia. Receiver operating characteristic (ROC) curves
were constructed and markers with area under ROC curve . 0.8
are considered indicative as biomarker.
Results
Course of S. aureus bacteremia
To establish the LD50 inoculum in the S. aureus bacteremia
model, groups of mice were intravenously infected with different
inocula (data not shown). S. aureus at 16104 CFU did not result in
mortality, while 26106 CFU S. aureus resulted in 100% mortality.
The LD50 inoculum was calculated to be 3 6 10
5 CFU. The
survival of mice infected with the LD50 inoculum declined
gradually over 14 days (Fig. 1A). After this time point, no changes
in animal survival were observed. Infected mice decreased in body
weight compared to placebo-inoculated mice. Body weight of
eventually non-surviving infected mice was significantly lower
compared to eventually surviving infected mice and to placebo-
inoculated mice (P , 0.01; Quade’s rank analysis of covariance;
Fig. 1B). Discomfort increased in all infected mice from two days
after infection. In surviving infected mice, this remained stable
until day 10 after infection and then decreased again, whereas the
discomfort score in non-surviving infected mice further increased.
Animals that showed severe signs of illness were euthanized and
were scored –4 (Fig. 1C). During the course of bacteremia, S. aureus
load in blood and organs did not significantly change over time
(Fig. 2). Only in kidneys, S. aureus load tended to increase over
time.
The course of S. aureus bacteremia was further characterized by
histopathology of lungs, spleen, liver, and kidneys. Organs of
infected mice that had to be euthanized early (day 4-5) and mice
that had to be euthanized later (day 10–11) were compared (Fig.
3). Most striking were renal bacterial abscesses in all euthanized
mice. Bronchopneumonia was observed in both early euthanized
mice and in one of the late euthanized mice. Bronchioles were
filled with neutrophils. The hepatic sinusoids were dilated with a
subtle increase of sinusoidal neutrophils in mice that had to be
euthanized early. Mice that had to be euthanized late also
developed hepatic microabscesses. The spleen showed lymphode-
pletion, which was more profound in late euthanized mice
compared to early euthanized mice. S. aureus was primarily found
intra- and perivascularly.
S. aureus load in blood in surviving infected mice versus
non-surviving infected mice
We determined whether conventional blood culture is indicative
for fatal infection outcome (Fig. 4). The number of animals with
positive blood cultures was not significantly different between
groups of surviving infected mice and non-surviving infected mice
at all time points. Quantitative blood cultures showed substantial
inter-individual variability. At 72 hours, CFU counts tended to be
higher in non-surviving infected mice compared to surviving
infected mice, although this was not statistically significant. Blood
cultures were negative in all surviving infected animals at 2 weeks
after inoculation (data not shown).
C-reactive protein levels in surviving infected mice versus
non-surviving infected mice
We determined whether serum CRP levels are indicative for
presence and fatal outcome of S. aureus bacteremia in mice (Fig. 5).
CRP levels were significantly elevated in infected mice compared
to placebo-inoculated mice at both 17 and 48 hours after infection
(P , 0.01). No significant differences were found between
surviving infected mice and non-surviving infected mice.
Cytokines in surviving infected mice versus non-surviving
infected mice
Serum levels of 31 selected cytokines were assessed. Significant
differences between S. aureus-infected mice versus placebo-inocu-
lated mice as well as between non-surviving infected mice versus
surviving infected mice are shown in Table 1.
Comparing infected mice to placebo-inoculated mice, 21
cytokines were elevated in infected mice (P , 0.01; Mann-
Whitney U test). From these, 3 cytokines (TNF-a, IL-6, and KC)
were already elevated early at 1 hour after infection and remained
elevated at 17 and 48 hours after infection. IL-10 was elevated at 1
and 17 hours as well, but was not elevated anymore at 48 hours.
At both 17 and 48 hours after infection, 12 cytokines were
elevated (G-CSF, M-CSF, IFN-c, IL-1a, IL-1b, IL-12p70, IL-15,
IL-17A, IP-10, MCP-1, MIG, and MIP-1a) in infected mice
compared to placebo-inoculated mice. GM-CSF, MIP-1a, MIP-2,
and RANTES were only elevated at 17 hours, while eotaxin was
only elevated at 48 hours after infection. Logistic regression
analysis showed that G-CSF, TNF-a, IL-1a, IL-6, IL-12p70, IP-
10, KC, and MIP-1a were discriminative between infected mice
and placebo-inoculated mice. Levels of these 8 cytokines in
individual mice are shown in Fig. 6. Levels of G-CSF showed an
impressive increase between 1 and 17 hours after infection, and
remained high at 48 hours. Levels of IL-12p70, IL-1a, IL-6, KC,
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and MIP-1a showed an increase between 1 and 17 hours as well,
although this increase was less pronounced than for G-CSF. The
levels of these 5 cytokines remained elevated at 48 hours. IP-10
levels showed an initial increase between 1 and 17 hours as well,
but decreased again between 17 and 48 hours. Levels of TNF-a
were elevated at 1, 17, and 48 hours. The elevated cytokine levels
in infected mice were not the result of animal handling during
blood drawing of blood, as cytokine levels in placebo-inoculated
mice were consistently low. Cytokine levels in surviving infected
mice decreased over time, and were near or comparable to those
in placebo-inoculated mice 2 weeks after inoculation (data not
shown).
Figure 1. Time course of bacteremia in mice infected with S. aureus at the LD50 inoculum. A Survival of infected mice (n = 25). B Mouse
body weight, shown as mean 6 SD (error bars). Body weight of non-surviving infected mice was significantly lower compared to surviving infected
mice and to placebo-inoculated mice (P , 0.01; Quade’s rank analysis of covariance). C Discomfort score, shown as mean 6 SD (error bars).
Discomfort score -2: bad fur. Discomfort score -3: bad fur, hunched back. Discomfort score -4: bad fur, hunched back, instability, euthanasia needed.
Placebo-inoculated mice (N n= 12), surviving infected mice (& n= 25), non-surviving infected mice (¤n= 25).
doi:10.1371/journal.pone.0059107.g001
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Comparing non-surviving infected mice to surviving infected
mice, we also found differences in the cytokine levels. Serum levels
of 5 cytokines were elevated in non-surviving infected mice
compared to surviving infected mice (P , 0.01; Mann-Whitney U
test). From these, KC was already elevated early at 1 hour after
infection in non-surviving infected mice, and remained elevated at
17 and 48 hours after infection. The other 4 cytokines (TNF-a, IL-
1a, IL-1b, and eotaxin) were elevated in non-surviving infected
mice only at 48 hours after infection. Logistic regression analysis
showed that TNF-a, IL-1a, and KC were discriminative between
non-surviving infected mice and surviving infected mice. Each of
the three cytokines showed an area under ROC curve . 0.8.
Combining these cytokines in the analysis did not further improve
the area under ROC curve.
Discussion
Early diagnosis of S. aureus bacteremia is crucial to reduce
mortality rates. In addition, optimization of antibiotic use is of
high importance. To this aim, novel and reliable markers as
predictors of infection outcome are urgently needed. In this study
in mice, we determined whether blood culture, CRP, and
cytokines are potential biomarkers for presence and outcome of
S. aureus bacteremia. We have established a model of S. aureus
bacteremia in mice that were S. aureus-free before infection. In this
way, all (immune) responses in these animals were due to the
inoculated S. aureus strain only. A clinical S. aureus isolate recovered
from a septic patient was used at an inoculum resulting in 50%
mortality of mice. This experimental design allowed comparison of
surviving and non-surviving mice infected with the same S. aureus
inoculum. Staphylococci mainly migrated to the kidneys, resulting
in an increase of bacterial load and bacterial microabscesses in the
kidneys were observed. Similar observations were described by
Cheng et al. [36]. The model proved to be very reproducible, and
provides a robust experimental system to investigate S. aureus
bacteremia.
When a patient is suspected of bacteremia, blood is drawn for
identification of the causative infectious agent, and cultured in
broth to make sure that low bacterial blood counts will also be
detected. Using this method, a quantitative blood culture cannot
be assessed. In the current study in mice, we investigated whether
presence of S. aureus bacteremia or S. aureus quantitative blood
counts are biomarkers predicting fatal outcome of S. aureus
bacteremia. A positive S. aureus blood culture did not discriminate
between eventually non-surviving infected mice and eventually
surviving infected mice. The S. aureus blood counts tended to be
higher in non-surviving infected mice compared to surviving
infected mice, but this was not statistically significant. We
concluded that neither the positive S. aureus blood culture nor
the S. aureus counts in blood could be used as biomarkers indicative
for fatal infection outcome.
We included CRP as a potential biomarker for presence and
fatal outcome of S. aureus bacteremia as this marker is frequently
used in clinical practice to determine and monitor inflammation
and infection in general. Circulating CRP levels directly reflect the
intensity of the pathological processes that stimulate the CRP
production [7]. The present study showed that CRP can be used
as a biomarker for presence of severe S. aureus bacteremia in mice.
However, serum CRP levels were not discriminative between
Figure 2. S. aureus counts in blood and organs from mice with bacteremia. At indicated time points after intravenous inoculation of S.
aureus at the LD50 inoculum, mice were sacrificed and quantitative cultures of blood and organs were performed (n = 4 per time point). Results are
expressed as mean 6 SD (error bars). Statistically significant differences (Mann-Whitney U test) in S. aureus load were not found. h, hours.
doi:10.1371/journal.pone.0059107.g002
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Figure 3. Representative histopathological features in lungs, spleen, liver and kidneys of mice with S. aureus bacteremia.
Haematoxylin and eosin stained tissue sections are shown. Lungs (2006), spleen (1006), liver (1006), and kidneys (1006). Uninfected mice; mice with
S. aureus bacteremia that were euthanized early (day 4-5); mice with S. aureus bacteremia that were euthanized later (day 10–11). In lungs, asterisk
indicates bronchopneumonia with neutrophils. In liver, arrow indicates hepathic microabscesses with neutrophils. In kidneys, arrows indicate
abscesses in kidneys.
doi:10.1371/journal.pone.0059107.g003
Figure 4. S. aureus counts in blood from mice with bacteremia at indicated time points. Mice were inoculated intravenously with S. aureus
at the LD50 inoculum (n= 25). Each symbol represents a single mouse. Median values are indicated by horizontal lines. Surviving infected mice (&),
non-surviving infected mice (e). Statistically significant differences in numbers of animals with positive blood cultures (Fisher exact test) or S. aureus
counts (Mann-Whitney U test) between groups of surviving infected mice versus non-surviving infected mice were never observed. h, hours.
doi:10.1371/journal.pone.0059107.g004
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Figure 5. Serum C-reactive protein (CRP) levels in mice with S. aureus bacteremia at indicated time points. Mice were inoculated
intravenously with S. aureus at the LD50 inoculum. Each symbol represents a single mouse. Red squares represent surviving infected mice (n = 10);
black diamonds represent non-surviving infected mice (n = 10); green circles represent placebo-inoculated mice (n = 10). Median values are presented
by horizontal lines. Statistically significant differences between infected mice and placebo-inoculated mice are indicated. Statistically significant
differences were never found between surviving infected mice and non-surviving infected mice. P-values, 0.01 (Mann-Whitney U test) are shown. h,
hours.
doi:10.1371/journal.pone.0059107.g005
Table 1. Cytokines in serum from mice with S. aureus bacteremia at various time points after infection.
Elevated due to infectiona
Elevated in non-surviving infected mice versus surviving
infected micea
Cytokine/chemokine 1h 17h 48h 1h 17h 48h
G-CSF ,0.0001 ,0.0001
GM-CSF 0.0044
M-CSF 0.0039 0.0099
IFN-c ,0.0001 0.0017
TNF-a ,0.0001 ,0.0001 ,0.0001 0.0004
IL-1a 0.0073 0.0001 0.0065
IL-1b 0.0037 0.0031 0.0028
IL-6 ,0.0001 ,0.0001 ,0.0001
IL-10 0.0001 0.0003
IL-12p70 ,0.0001 0.0001
IL-15 0.0001 0.0003
IL-17A 0.0002 0.0007
eotaxin (CCL1) 0.0012 0.0025
IP-10 (CXCL10) ,0.0001 0.0008
KC (CXCL1) 0.0089 ,0.0001 ,0.0001 0.0043 0.0025 0.0090
MCP-1 (CCL2) ,0.0001 ,0.0001
MIG (CXCL9) 0.0001 0.0008
MIP-1a (CCL3) 0.0001 0.0019
MIP-1b (CCL4) 0.0015
MIP-2 (CXCL2) 0.0003
RANTES (CCL5) 0.0024
aOnly P-values for the 21 cytokines that were significantly elevated (Mann-Whitney U test, P , 0.01) in infected mice (n = 20) compared to placebo-inoculated mice
(n = 10) are shown. Cytokines for which area under ROC curve was . 0.8 (logistic regression analysis) are indicated in bold.
doi:10.1371/journal.pone.0059107.t001
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surviving infected mice and non-surviving infected mice, and
therefore CRP is not a biomarker for fatal outcome of infection.
These data in mice are in concordance with findings in bacteremic
patients, as CRP is a biomarker for presence of S. aureus
bacteremia, but does not predict outcome of infection [6]. As
CRP is not specific for S. aureus infection, elevated CRP levels will
not indicate bacteremia caused by S. aureus only.
In addition, we assessed whether cytokines can be used as
biomarker in S. aureus bacteremia. According to the binary logistic
regression analysis, TNF-a, IL-1a, KC, G-CSF, IL-6, IL-12p70,
IP-10, and MIP-1a are indicative for presence of S. aureus
bacteremia in mice, while TNF-a, IL-1a, and KC were also
potential biomarkers for fatal outcome of this infection. As the last
three cytokines each had a very high area under ROC curve, and
combination of these cytokines did not improve this, each of these
can be used individually as biomarkers for fatal outcome.
Diagnosis of S. aureus bacteremia cannot be based solely on
elevated levels of these cytokines, as cytokine levels will rise in
other infections as well. Until now, cytokine levels in mice with S.
aureus bacteremia are not well studied. Ashare et al. assessed
cytokine levels in a murine model simulating polymicrobial sepsis
and showed that levels of TNF-a and IL-1b in liver were elevated
in septic mice compared to controls [37]. Osuchowski et al., using
the same murine model, showed that plasma levels of MCP-1,
MIP-2, and TNF-a had a robust correlation with outcome of
infection [38]. Discrepancies between these studies and the present
study could be explained by differences in the biomaterial in which
cytokines were measured, differences in the causative infectious
organism(s), and differences in cytokines included for assessment in
these studies. In the present study, we selected a broad panel
containing 31 cytokines, covering the main cytokines found in
related studies, and including both pro- and anti-inflammatory
cytokines. Most other studies measured only a limited number of
cytokines, up to 16.
In the present study, 3 cytokines (TNF-a, IL-1a, and KC)
emerged as biomarkers for fatal outcome of S. aureus bacteremia.
TNF-a is primarily produced by activated macrophages and
stimulates the acute phase reaction. It induces apoptotic cell death,
attracts neutrophils and stimulates phagocytosis. IL-1a is also
mainly produced by activated macrophages early after onset of
infection, and plays one of the central roles in the regulation of
immune responses. It activates lymphocyte proliferation and
increases number of blood neutrophils. KC is the murine
functional homologue of human IL-8 [35] and is an important
neutrophil chemoattractant. Neutrophils appear to be important
in S. aureus sepsis, as TNF-a, IL-1a and KC/IL-8 all attract these
cells. In patients with S. aureus bacteremia, neutrophils are
activated as well [39]. At both 1 and 17 and 48 hours after
infection, KC was elevated in non-surviving infected mice
compared to surviving infected mice. A biomarker elevated
irrespective the progression of infection, such as KC, is very
interesting for clinical application in view of the heterogeneity of
patients experiencing bacteremia in this respect.
In the present study, we exhaustively examined blood culture,
CRP and cytokines as biomarkers for presence of severe S. aureus
bacteraemia and fatal outcome of infection in mice. This study
provides evidence that in severe S. aureus bacteremia in mice, TNF-
a, IL-1a, and KC each can be useful as biomarkers predicting fatal
outcome of infection. Blood cultures (qualitative or quantitative)
and CRP are not discriminative in this respect. As elevated levels
of these cytokines are indicative for S. aureus bacteremia, these
cytokines cannot be used to diagnose S. aureus bacteremia; instead
these cytokines might be useful as biomarkers for outcome of
infection in patients already diagnosed with S. aureus bacteremia.
Several clinical studies have shown that it is difficult to evaluate
changes in cytokine profile during bacteremia in patients, and this
is mainly due to differences in causative infectious agents. Studies
focused on a single, known causative infectious organism might be
more informative. In the clinical setting, infecting S. aureus strains
will vary between patients. In the present study in mice, only one
S. aureus clinical isolate was used. So, we should be careful in
extrapolating the results obtained in mice to the clinical setting. As
the host as well as the S. aureus strain are both important
determinants in the infectious process, and only one mouse strain
and one S. aureus strain were included in the present study, it is
currently unknown whether the observations obtained can be
generalized. Therefore, we conclude that the current results in
mice suggest that cytokines might be reliable biomarkers for fatal
outcome of S. aureus bacteremia in patients. Currently, data on
appropriate biomarkers are lacking and only when bacteremia is
strongly suspected in patients, antibiotic treatment is started. Based
on the present study in mice, a clinical study on the role of selected
cytokines in predicting the infection outcome is warranted. These
data will improve decisions on the start and choice of antibiotic
therapy.
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